The Oncotype DX 21-gene Recurrence Score (RS) was developed in order to determine the likelihood of distant recurrence of early-stage breast cancer patients who initially were diagnosed with node-negative, ER+ luminal type breast cancer treated with tamoxifen [44,45]. Here, ESR1 is linked to breast carcinoma.